L16 Therapeutics of Asthma

Descripción

PHCY310 Test sobre L16 Therapeutics of Asthma, creado por Mer Scott el 12/04/2019.
Mer Scott
Test por Mer Scott, actualizado hace más de 1 año
Mer Scott
Creado por Mer Scott hace más de 5 años
8
0

Resumen del Recurso

Pregunta 1

Pregunta
Clinical practice guidelines, meta-analysis, and systematic reviews are the highest ranked forms of evidence.
Respuesta
  • True
  • False

Pregunta 2

Pregunta
Māori are 3.4 times, and Pacific peoples 3.9 times, more likely to be admitted to hospital with asthma than Europeans or other New Zealanders.
Respuesta
  • True
  • False

Pregunta 3

Pregunta
When diagnosing asthma there is no single “gold standard” test, and we must assess the pattern of [blank_start]signs and symptoms[blank_end](wheezing, breathlessness, chest tightness, and coughing, particularly at [blank_start]night[blank_end] or [blank_start]early[blank_end] in the morning). We can also measure [blank_start]expiratory airflow[blank_end] on more than one occasion, and assess [blank_start]response[blank_end] to inhaled bronchodilator +/- inhaled corticosteroid.
Respuesta
  • signs and symptoms
  • night
  • early
  • expiratory airflow
  • response

Pregunta 4

Pregunta
Ideal PEFR values depend on height and sex.
Respuesta
  • True
  • False

Pregunta 5

Pregunta
Which of these is NOT a principle of asthma treatment?
Respuesta
  • Avoid triggers
  • Making an asthma plan
  • Drugs to improve ventilation
  • Drugs to decrease inflammation
  • Avoid exercise

Pregunta 6

Pregunta
Goals of asthma treatment are about maintaining long-term control using the [blank_start]least[blank_end] amount of medications and [blank_start]minimising[blank_end] adverse effects. We want to prevent chronic [blank_start]symptoms[blank_end], require infrequent use ([blank_start]2[blank_end] or fewer days/week) of SABA, maintain normal or near-normal [blank_start]pulmonary[blank_end] function and maintain [blank_start]activity[blank_end] levels. We should assure patients’ and families’ [blank_start]satisfaction[blank_end] with asthma care. We also want to prevent exacerbations, the need for [blank_start]hospitalisation[blank_end], and prevent progressive [blank_start]loss[blank_end] of lung function.
Respuesta
  • least
  • minimising
  • symptoms
  • 2
  • pulmonary
  • activity
  • satisfaction
  • hospitalisation
  • loss

Pregunta 7

Pregunta
Which of these is not a drug delivery device?
Respuesta
  • Soft mist inhaler (SMI) - only with LAMA products in NZ
  • Nebuliser
  • Dry power inhaler (DPI)
  • Metered-dose inhaler (MDI) - spacer chamber
  • Dry mist inhaler (DMI)

Pregunta 8

Pregunta
Treatment steps: 1. At initial diagnosis, all patients should use a [blank_start]SABA[blank_end], as required.. 2. Add an [blank_start]ICS[blank_end] if patients have symptoms for more than [blank_start]two[blank_end] weeks. Often a big decision! (The usual dose in adults is [blank_start]budesonide 400 mcg[blank_end]/day.) 3. If control is not adequate, [blank_start]ICS dose[blank_end] can be increased. 4. If control is not adequate, combine [blank_start]ICS with a LABA[blank_end]. ([blank_start]Formoterol+budesonide[blank_end] can be used as a preventer and replace SABA.) Patients can step up or down in order to achieve and maintain control. Check adherence and inhaler [blank_start]technique[blank_end] at each step of the way!
Respuesta
  • SABA
  • ICS
  • two
  • budesonide 400 mcg
  • ICS dose
  • ICS with a LABA
  • Formoterol+budesonide
  • technique
Mostrar resumen completo Ocultar resumen completo

Similar

Resumen sobre Los Reyes Católicos
maya velasquez
Mapa conceptual de la materia.
gaby271975
Qué Carrera Estudiar
Diego Santos
Aula Invertida
Diego Santos
ORGANIGRAMA
Sebastian Valencia
Línea del Tiempo: La Creación de la Tierra
Valdeavellano
linea del tiempo de la evolución del microscopio
elsa garcia
Autores vacío
Manu prieto
Enlaces Químicos
Camila Barbosa
Micosis cutáneas (Dermatofitosis)
MED
Roles en la educación inclusiva
Alejandro Villamizar